Modality
Nanobody
MOA
Menini
Target
B7-H3
Pathway
PI3K/AKT
Atopic Derm
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
~Sep 2017
→ ~Dec 2018
Phase 3
~Mar 2019
→ ~Jun 2020
NDA/BLA
~Sep 2020
→ ~Dec 2021
Approved
Mar 2022
→ Feb 2026
ApprovedCurrent
NCT08255103
847 pts·Atopic Derm
2022-03→2026-02·Active
847 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2026-02-052mo agoPh3 Readout· Atopic Derm
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
Approved
Active
Catalysts
Ph3 Readout
2026-02-05 · 2mo ago
Atopic Derm
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08255103 | Approved | Atopic Derm | Active | 847 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP |